Galectin Therapeutics Inc. (NASDAQ:GALT) announced its earnings results on Tuesday, November 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02, Bloomberg Earnings reports.
Galectin Therapeutics (NASDAQ:GALT) traded up $0.01 on Thursday, hitting $2.87. The company’s stock had a trading volume of 220,500 shares, compared to its average volume of 358,012. Galectin Therapeutics has a 1 year low of $0.81 and a 1 year high of $3.68.
An institutional investor recently raised its position in Galectin Therapeutics stock. Northern Trust Corp boosted its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 4.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,097 shares of the company’s stock after purchasing an additional 3,176 shares during the period. Northern Trust Corp owned about 0.22% of Galectin Therapeutics worth $185,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.16% of the company’s stock.
GALT has been the subject of several recent analyst reports. ValuEngine downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Seaport Global Securities reissued a “buy” rating and issued a $5.00 target price on shares of Galectin Therapeutics in a report on Friday, October 6th. Finally, Roth Capital started coverage on Galectin Therapeutics in a report on Thursday, October 19th. They issued a “buy” rating and a $8.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Galectin Therapeutics currently has an average rating of “Hold” and a consensus price target of $4.63.
ILLEGAL ACTIVITY NOTICE: This story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://ledgergazette.com/2017/11/16/galectin-therapeutics-inc-galt-posts-earnings-results-beats-expectations-by-0-02-eps.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.